Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives $12.38 Average PT from Analysts

Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) have received a consensus rating of "Buy" from the five analysts that are currently covering the stock, Marketbeat.com reports. Four investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $12.38.

Separately, HC Wainwright reaffirmed a "buy" rating and set a $11.00 price objective on shares of Corvus Pharmaceuticals in a research report on Tuesday, January 14th.

Corvus Pharmaceuticals Stock Up 2.4 %

Shares of NASDAQ:CRVS traded up $0.10 on Tuesday, hitting $4.31. The company had a trading volume of 686,035 shares, compared to its average volume of 561,739. The firm's 50-day simple moving average is $4.76 and its two-hundred day simple moving average is $6.07. The firm has a market capitalization of $276.95 million, a price-to-earnings ratio of -4.63 and a beta of 0.91. Corvus Pharmaceuticals has a 1 year low of $1.30 and a 1 year high of $10.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Oppenheimer & Co. Inc. purchased a new stake in shares of Corvus Pharmaceuticals in the third quarter worth $89,000. Connor Clark & Lunn Investment Management Ltd. grew its position in Corvus Pharmaceuticals by 64.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 137,031 shares of the company's stock valued at $724,000 after purchasing an additional 53,809 shares during the last quarter. Nwam LLC purchased a new stake in Corvus Pharmaceuticals during the 3rd quarter valued at about $53,000. State Street Corp increased its stake in Corvus Pharmaceuticals by 48.2% during the 3rd quarter. State Street Corp now owns 178,246 shares of the company's stock valued at $941,000 after purchasing an additional 57,943 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in Corvus Pharmaceuticals in the third quarter worth about $265,000. Institutional investors own 46.64% of the company's stock.

Remove Ads

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.